Table 7 A comparison of BCMA-targeted treatment modalities in RRMM

Logistics

Manufacturing time bridging therapy required

Hospital infrastructure

Off the shelf

Off the shelf

Setting

Inpatient

Inpatient- > outpatient

Outpatient

Treatment

One time treatment

Mostly weekly dosing

Until PD

Q3w dosing

Until PD

Clinical benefit

ORR 80%

Promising PFS and MRD data

ORR 60–80%

PFS data N/A

ORR 30%

Modest PFS with single agent

Adverse effects

CRS 70–90%

(Grade >  = 3: 5–10%)

Neurotoxicity

Lymphodepletion

CRS 35–80%

(> = Grade3: 5–10%)

Neurotoxicity

Keratopathy

(> = Grade3: 20–25%)

Thrombocytopenia

Host T cell dependency

Yes except in universal CAR-T/NK

Yes

No